• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Sun Life Financial
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

7.060 -0.380 (-5.11%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 235,176
Open 7.380
Bid (Size) 6.220 (100)
Ask (Size) 7.400 (100)
Prev. Close 7.440
Today's Range 6.975 - 7.430
52wk Range 6.780 - 34.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
November 16, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
November 09, 2026
From Oculis Holding AG
Via GlobeNewswire

Performance

52-Week Range 79.5% below 52-week high
7.060
6.7852W Low 34.4852W High
1 Week 14.0% below 1-week high
6.971W Low 8.211W High

Oculis Holding AG - Ordinary shares (OCS) traded between $6.78 and $34.48 over the past 52 weeks and last traded at $7.06, 79.5% below its 52-week high. Over the past week it ranged between $6.97 and $8.21.

Past 12 Months
-7.5%
-10.3%
-46.0%
-76.1%
-64.7%
-63.3%
1W -$0.57
1M -$0.81
3M -$6.03
6M -$22.43
YTD -$12.94
1Y -$12.16

OCS was -63.3% over the past year, -76.1% over six months, -64.7% year to date, -7.5% in the last week.

12 Months vs Market
OCS
-63.3%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months OCS returned -63.3% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.87× 3-mo avg
Today 235,176 3-mo avg 269.9K
1W
230.3K
1M
296.4K
3M
269.9K
6M
454.6K
YTD
412.7K
1Y
378.5K

OCS most recently traded 235,176 shares against a 3-month average daily volume of 269.9K.

More News

Read More
Oculis Holding AG (NASDAQ:OCS) Q3 Loss Narrows as Year-End Clinical Catalysts Near ↗
November 03, 2026
Via Chartmill
News headline image
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
November 03, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
November 02, 2026
From Oculis Holding AG
Via GlobeNewswire
Oculis (NASDAQ:OCS) Beats Q2 Estimates and Advances Late-Stage Neuro-Ophthalmology Pipeline ↗
August 06, 2026
Via Chartmill
News headline image
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
October 29, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
October 22, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
October 20, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
October 19, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 07, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 01, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 30, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 06, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
August 03, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
July 02, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
June 23, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
June 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
June 16, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
June 11, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
June 09, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 09, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 08, 2026
From Oculis Holding AG
Via GlobeNewswire

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 7.060
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 11/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap